Foamix Pharmaceuticals (NASDAQ:FOMX) and Entia Biosciences (OTCMKTS:ERGO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
This table compares Foamix Pharmaceuticals and Entia Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Foamix Pharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Entia Biosciences has a beta of 4.68, meaning that its stock price is 368% more volatile than the S&P 500.
Institutional & Insider Ownership
62.6% of Foamix Pharmaceuticals shares are owned by institutional investors. 3.3% of Foamix Pharmaceuticals shares are owned by insiders. Comparatively, 28.3% of Entia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Foamix Pharmaceuticals and Entia Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Foamix Pharmaceuticals||$3.67 million||54.58||-$65.71 million||($1.76)||-2.10|
|Entia Biosciences||$260,000.00||2.49||-$1.39 million||N/A||N/A|
Entia Biosciences has lower revenue, but higher earnings than Foamix Pharmaceuticals.
This is a breakdown of recent ratings for Foamix Pharmaceuticals and Entia Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Foamix Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 378.77%. Given Foamix Pharmaceuticals’ higher possible upside, research analysts plainly believe Foamix Pharmaceuticals is more favorable than Entia Biosciences.
Entia Biosciences beats Foamix Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.
About Entia Biosciences
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.